ResMed Inc. (RMD) Balance Sheet

The sequential increase in total assets, driven largely by a $1.3B rise in cash and a $600M increase in goodwill, suggests the company is accumulating liquidity and expanding through acquisitions. Equity expanded from $4.6B to $6.6B, reflecting retained earnings growth, which supports a trajectory of financial resilience. However, the goodwill jump in 2026Q4 warrants monitoring for potential impairment risk.

The reduction in absolute debt and leverage ratio suggests that ResMed is not reliant on debt financing for growth, and its cash position now exceeds total debt, providing a net cash position. This conservative capital structure implies strong financial flexibility and low refinancing risk, though the slight uptick in debt in 2026Q2 may reflect opportunistic borrowing.

The increasing goodwill balance, likely from acquisitions, indicates a strategy of inorganic growth, but it also elevates the risk of future impairment charges if acquired businesses underperform. PPE growth has been modest, suggesting an asset-light manufacturing model, but the recent capex spike in 2026Q4 may signal a shift toward more tangible investment.

The substantial increase in retained earnings underscores strong profitability and a policy of reinvesting profits, which bolsters equity quality. However, the elevated SBC in the latest quarter, if sustained, could dilute existing shareholders and partially offset the equity build, warranting close monitoring.

The current ratio consistently above 2.5 indicates strong short-term solvency, and the cash balance now covers nearly two quarters of operating expenses, based on historical burn rates. This liquidity position suggests the company can fund strategic initiatives or weather demand fluctuations without stress.